Retatrutide vs Every GLP-1: Why Triple Beats All

Retatrutide is technically not just a GLP-1 agonist — it is a triple agonist that includes GLP-1 activation alongside GIP and glucagon receptor activation. But because it competes in the same therapeutic space, comparing retatrutide to every GLP-1-class medication reveals why adding receptors matters so much for weight loss outcomes. From first-generation liraglutide to next-generation orforglipron, retatrutide's 24.2% weight loss in Phase 2 (Jastreboff et al., NEJM 2023) exceeds them all.

GLP-1 Class Evolution

The Pattern: More Receptors = More Weight Loss

The data tells a clear story. Single GLP-1 agonists (exenatide, liraglutide, semaglutide) top out at roughly 15% weight loss with the most potent agent. Adding GIP (tirzepatide) pushes to 22.5%. Adding glucagon (retatrutide) pushes to 24.2% and still climbing. Each additional receptor target provides incremental but meaningful weight loss benefits.

This pattern makes biological sense. GLP-1 alone reduces appetite and slows gastric emptying. Adding GIP improves how the body handles fats and enhances insulin sensitivity. Adding glucagon does something no GLP-1 can do — it increases energy expenditure, essentially speeding up metabolism rather than just reducing food intake.

Why Semaglutide Was a Breakthrough

Before comparing everything to retatrutide, it is worth acknowledging that semaglutide (Wegovy/Ozempic) was the drug that transformed obesity medicine. It proved that a once-weekly injection could produce 15% weight loss — enough to change cardiovascular outcomes, resolve sleep apnea, and transform patients' lives. Without semaglutide's success, the investment in multi-receptor drugs like tirzepatide and retatrutide might not have happened.

Retatrutide's Unique Advantages Over All GLP-1s

• Energy expenditure: The only drug in the class that actively increases caloric burn through glucagon activation
• Liver fat: Direct hepatic fat oxidation via glucagon — no other GLP-1 does this
• Speed: 24.2% in 48 weeks vs tirzepatide's 22.5% in 72 weeks — roughly 60% faster rate
• No plateau: Weight loss curve was still declining at study end, suggesting greater total loss with longer treatment
• Body composition: Glucagon-mediated effects may preferentially target visceral fat

Best Available Treatment Today

While retatrutide represents the future, the best available GLP-1 medications are accessible and affordable right now. Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month. These medications produce 15-22% weight loss — results that were unimaginable just a few years ago. When retatrutide becomes available, Trimi plans to offer it as well. Get started today.

Frequently Asked Questions

Is retatrutide the best GLP-1 medication?

Technically, retatrutide is a triple agonist, not a pure GLP-1. But among all drugs in the GLP-1 class family, yes — it produces the most weight loss based on available data.

What is the best GLP-1 available right now?

Tirzepatide (Zepbound/Mounjaro) at 22.5% average weight loss is the most effective currently available option. Compounded tirzepatide is available through Trimi at $125/month.

Will there be a quadruple agonist after retatrutide?

Research into quadruple and beyond combinations is ongoing, but adding receptors also increases side effect complexity. The diminishing returns of each additional target may limit how far multi-receptor approaches can go.

Are all GLP-1 medications basically the same?

No. While they share the GLP-1 receptor as a common target, the differences in potency, receptor selectivity, half-life, and additional receptor targets produce dramatically different clinical outcomes — from 3% to 24% weight loss across the class.